Wednesday, July 7, 2021, 5:00 PM – 6:00 PM Eastern Time (ET)

A Conversation with the Investigators: Ovarian Cancer

A Live CME/MOC Webinar Held Adjunct to the 2021 ASCO Annual Meeting

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.


Join us on Wednesday, July 7th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty

Michael J Birrer, MD, PhD
Vice Chancellor, UAMS
Director, Winthrop P Rockefeller Cancer Institute
Director, Cancer Service Line
University of Arkansas for Medical Sciences
Little Rock, Arkansas

Kathleen Moore, MD
The Virginia Kerley Cade Endowed Chair in Cancer Development
Associate Director, Clinical Research
Director, Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor, Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Additional faculty to be announced.

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, GlaxoSmithKline, ImmunoGen Inc and Merck.

Ovarian Cancer (OC)

  • Frequency and clinical significance of BRCA1/2 mutations and other genomic abnormalities (eg, homologous recombination deficiency) that may predict sensitivity to a PARP inhibitor
  • Guideline-recommended genetic testing algorithms for patients with newly diagnosed OC
  • Key clinical and biologic factors in the selection of patients with newly diagnosed OC for maintenance therapy with a PARP inhibitor
  • Major efficacy and safety findings from the pivotal Phase III SOLO-1 trial evaluating maintenance olaparib after first-line platinum-based chemotherapy for patients with advanced OC and a BRCA mutation
  • Results of the Phase III PRIMA trial evaluating maintenance niraparib after first-line platinum-based chemotherapy for patients with advanced OC
  • Design, eligibility criteria and efficacy and safety data from the Phase III PAOLA-1 trial comparing olaparib/bevacizumab to bevacizumab for advanced OC
  • FDA approvals of olaparib and niraparib in the front-line OC setting and integration into the management of newly diagnosed disease
  • Similarities and differences between veliparib and other approved PARP inhibitors; biologic rationale for combining veliparib with chemotherapy for OC
  • Key efficacy and safety data from the Phase III VELIA trial evaluating the addition of veliparib to first-line chemotherapy and as maintenance therapy for high-grade OC
  • Biologic rationale for and published research data (eg, from the TOPACIO and MEDIOLA trials) with the combination of PARP inhibitors and anti-PD-1/PD-L1 antibodies
  • Ongoing Phase III trials evaluating PARP inhibitors with immunotherapy for OC
  • Mechanism of action of and available clinical trial data with mirvetuximab soravtansine as monotherapy or in combination with other effective therapies (eg, bevacizumab) for patients with folate receptor alpha-positive advanced OC

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of ovarian cancer.

Learning Objectives

  • Appraise guideline recommendations, consensus statements and clinical investigator perspectives regarding the indications for and selection of genetic testing platforms in ovarian cancer (OC), and use the results of these assessments to guide long-term treatment.
  • Consider the FDA approval of olaparib as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced OC harboring a deleterious or suspected deleterious BRCA germline or somatic mutation, and counsel appropriate individuals regarding personalized treatment recommendations.
  • Recognize the recent FDA approval of niraparib as maintenance therapy in the first-line setting for patients with advanced OC with or without BRCA mutations, and discern for which individuals treatment with this agent may be appropriate.
  • Evaluate available clinical trial data leading to the recent FDA approval of olaparib/bevacizumab as first-line maintenance therapy for patients with newly diagnosed OC responding after platinum-taxane chemotherapy with bevacizumab in order to determine the role of this novel strategy in clinical practice.
  • Assess available clinical trial data with and approved indications for FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiregimen-refractory OC in order to personalize care plans incorporating these agents.
  • Recognize the toxicities associated with PARP inhibitors commonly used in the care of patients with OC, and offer supportive management strategies to minimize or ameliorate these side effects.
  • Develop an understanding of the rationale for, emerging data with and potential clinical role of combining PARP inhibitors with anti-PD-1/PD-L1 antibodies, and counsel appropriate patients about the availability of and participation in research studies.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, GlaxoSmithKline, ImmunoGen Inc and Merck.